Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 2/20 | 0.33 |
| ▸ | CCND1 | P24385 | 2/20 | 0.33 |
| ▸ | CCND2 | P30279 | 2/20 | 0.33 |
| ▸ | CCND3 | P30281 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | GPR183 | P32249 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669160 | 0.66 | MAPK14 (0.45) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL14012593 | 0.66 | TSHR (0.39) | LMNASMN1; SMN2MEN1NPC1GALR3 | |
| SCHEMBL25885476 | 0.63 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL10233349 | 0.63 | NPC1 (0.47) | CA12CA9LMNASMN1; SMN2MEN1 | |
| SCHEMBL26155648 | 0.61 | CYP1A2 (0.40) | PDE1CLMNASMN1; SMN2MEN1NPC1 | |
| SCHEMBL25696305 | 0.61 | KMO (0.45) | LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL26597002 | 0.61 | CYP17A1 (0.34) | PDE1CLMNASMN1; SMN2 | |
| SCHEMBL24246582 | 0.61 | LMNA (0.33) | LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL10050859 | 0.61 | RECQL (0.43) | LMNASMN1; SMN2MEN1NPC1RAB9A | |
| SCHEMBL1356214 | 0.61 | BRPF1 (0.53) | BRPF1CA12BRD4CA9KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435987-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110294805-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022085-B2 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-7846944-B2 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2152706-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | Amgen Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| EP-2152704-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | Amgen, Inc (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008137176-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008136948-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294805-A1 | PYRAZOLO-PYRIDINONE AND PYRAZOLO-PYRAZINONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF | MAPK1, MAP4K2, MAP3K1 | BRPF1 1050/4885CA12 4847/4885BRD4 1096/4885 |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | MAPK1, MAP3K1, MAP4K2 | BRPF1 1398/4885CA12 4805/4885BRD4 1022/4885 |
| US-20110105498-A1 | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof | MAPK1, MAP4K2, MAP3K1 | BRPF1 1050/4885CA12 4847/4885BRD4 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.